Skip Navigation U.S. Department of Health and Human Services www.hhs.gov
Agency for Healthcare Research Quality www.ahrq.gov
Archive print banner
Report on the Relative Efficacy of Oral Cancer Therapy for Medicare Beneficiaries Versus Currently Covered Therapy

This information is for reference purposes only. It was current when produced and may now be outdated. Archive material is no longer maintained, and some links may not work. Persons with disabilities having difficulty accessing this information should contact us at: https://info.ahrq.gov. Let us know the nature of the problem, the Web address of what you want, and your contact information.

Please go to www.ahrq.gov for current information.

Part 4. Thalidomide for Multiple Myeloma (continued)


References

1. Dimopoulos MA, Anagnostopoulos A, Weber D. Treatment of plasma cell dyscrasias with thalidomide and its derivatives [Review]. Journal of Clinical Oncology 2003;21(23):4444-4454.

2. Kyle RA. Clinical and laboratory manifestations of multiple myeloma. Up-to-date [www.uptodate.com]. Accessed July 15, 2005.

3. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. British Journal of Haematology Jun 2003;121(5):749-757.

4. American Cancer Society. Cancer Facts and Figures 2005. 2005; http://www.cancer.org/docroot/STT/stt_0.asp. Accessed March 25, 2005.

5. Lynch HT, Watson P, Tarantolo S, et al. Phenotypic Heterogeneity in Multiple Myeloma Families. Journal of Clinical Oncology Feb 1, 2005;23(4):685-693.

6. Kyle RA. "Benign" monoclonal gammopathy—after 20 to 35 years of follow-up. Mayo Clinic Proceedings Jan 1993;68(1):26-36.

7. Grethlein S. Multiple myeloma. eMedicine. http://www.emedicine.com/med/topic1521.htm. Accessed July 16, 2005.

8. Kyle RA, Rajkumar SV. Multiple myeloma [see comment][erratum appears in N Engl J Med 2005 Mar 17;352(11):1163]. New England Journal of Medicine Oct 28 2004;351(18):1860-1873.

9. Kyle R. Multiple myeloma. In: Dollinger M, Rosenbaum E, Cable G, eds. Everybody's Guide to Cancer Therapy; 1997:592-599.

10. Kyle RA. Diagnosis and differential diagnosis of multiple myeloma. Up-to-date [www.uptodate.com]. Accessed July 15, 2005.

11. Greipp PR. Smoldering, asymptomatic stage 1, and indolent myeloma [Review]. Current Treatment Options in Oncology 2000;1(2):119-126.

12. National Cancer Institute. Multiple Myeloma and Other Plasma Cell Neoplasms (PDQ®): Treatment.á http://www.cancer.gov/cancertopics/pdq/treatment/CML/HealthProfessional/page4#Reference4.32. Accessed July 15, 2005.

13. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer Sep 1975;36(3):842-854.

14. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. Journal of Clinical Oncology May 20 2005;23(15):3412-3420.

15. Durie BG, Stock-Novack D, Salmon SE, et al. Prognostic value of pretreatment serum beta 2 microglobulin in myeloma: a Southwest Oncology Group Study [see comment]. Blood Feb 15 1990;75(4):823-830.

16. American Cancer Society. How is multiple myeloma treated? 2005; http://www.cancer.org/docroot/STT/stt_0.asp. Accessed July 15, 2005.

17. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. British Journal of Haematology Sep 1998;102(5):1115-1123.

18. Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma [see comment]. Mayo Clinic Proceedings Jan 2003;78(1):21-33.

19. Fonseca R, Blood E, Rue M, et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood Jun 1 2003;101(11):4569-4575.

20. Kumar S, Fonseca R, Dispenzieri A, et al. Bone marrow angiogenesis in multiple myeloma: effect of therapy. British Journal of Haematology Dec 2002;119(3):665-671.

21. Lee CK, Barlogie B, Munshi N, et al. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. Journal of Clinical Oncology 2003;21(14):2732-2739.

22. Riccardi A, Mora O, Tinelli C, et al. Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study. Cooperative Group of Study and Treatment of Multiple Myeloma. British Journal of Cancer Apr 2000;82(7):1254-1260.

23. He Y, Wheatley K, Clark O, et al. Early versus deferred treatment for early stage multiple myeloma. Cochrane Database of Systematic Reviews 2003;(1):CD004023.

24. Myeloma Trialists' Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Journal of Clinical Oncology Dec 1998;16(12):3832-3842.

25. Oken MM, Harrington DP, Abramson N, et al. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479. Cancer Apr 15 1997;79(8):1561-1567.

26. Kildahl-Andersen O, Bjark P, Bondevik A, et al. Multiple myeloma in central and northern Norway 1981-1982: a follow-up study of a randomized clinical trial of 5-drug combination therapy versus standard therapy. European Journal of Haematology Jul 1988;41(1):47-51.

27. Kildahl-Andersen O, Bjark P, Bondevik A, et al. Multiple myeloma in central Norway 1981-1982: a randomized clinical trial of 5-drug combination therapy versus standard therapy. Scandinavian Journal of Haematology Sep 1986;37(3):243-248.

28. Hansen OP, Clausen NA, Drivsholm A, et al. Phase III study of intermittent 5-drug regimen (VBCMP) versus intermittent 3-drug regimen (VMP) versus intermittent melphalan and prednisone (MP) in myelomatosis. Scandinavian Journal of Haematology Nov 1985;35(5):518-524.

29. Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. New England Journal of Medicine May 24 1984;310(21):1353-1356.

30. Samson D, Gaminara E, Newland A, et al. Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma [see comment]. Lancet Oct 14 1989;2(8668):882-885.

31. Anderson H, Scarffe JH, Ranson M, et al. VAD chemotherapy as remission induction for multiple myeloma. British Journal of Cancer Feb 1995;71(2):326-330.

32. Segeren CM, Sonneveld P, van der Holt B, et al. Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma. British Journal of Haematology Apr 1999;105(1):127-130.

33. Mineur P, Menard JF, Le Loet X, et al. VAD or VMBCP in multiple myeloma refractory to or relapsing after cyclophosphamide-prednisone therapy (protocol MY 85). British Journal of Haematology Nov 1998;103(2):512-517.

34. Dimopoulos MA, Pouli A, Zervas K, et al. Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma. Annals of Oncology Jul 2003;14(7):1039-1044.

35. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma [erratum appears in N Engl J Med 2000 Feb 3;342(5):364]. New England Journal of Medicine 1999;341(21):1565-1571.

36. Lentzsch S, Rogers MS, LeBlanc R, et al. S-3-Amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice. Cancer Research 2002;62(8):2300-2305.

37. Olson K, Hall T, Horton J, et al. Thalidomide (N-phthaloylglutamimide) in the treatment of advanced cancer. Clinical Pharmacology and Therapeutics 1965;6:292-297.

38. Eriksson T, Bjorkman S, Hoglund P. Clinical pharmacology of thalidomide. European Journal of Clinical Pharmacology Aug 2001;57(5):365-376.

39. Ramos J. Thalidomide: Price increases for cancer treatment.á http://www.essentialdrugs.org/edrug/archive/200508/msg00053.php. Accessed Aug 26, 2005.

40. National Institute for Clinical Excellence. Gefitinib for non-small cell lung cancer—appraisal (project). London: National Institute for Clinical Excellence.

41. Rajkumar SV, Dispenzieri A, Fonseca R, et al. Thalidomide for previously untreated indolent or smoldering multiple myeloma. Leukemia 2001;15(8):1274-1276.

42. Rajkumar SV, Gertz MA, Lacy MQ, et al. Thalidomide as initial therapy for early-stage myeloma. Leukemia 2003;17(4):775-779.

43. Barlogie B, Desikan R, Eddlemon P, et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001;98(2):492-494.

44. Corso A, Lorenzi A, Orlandi E, Astori C, Mangiacavalli S, Lazzarino M. Advantages of using thalidomide for the management of refractory myeloma patients. Haematologica 2002;87(3):328-328.

45. Hattori Y, Kakimoto T, Okamoto S, et al. Thalidomide-induced severe neutropenia during treatment of multiple myeloma. International Journal of Hematology 2004;79(3):283-288.

46. Hus M, Dmoszynska A, Soroka-Wojtaszko M, et al. Thalidomide treatment of resistant or relapsed multiple myeloma patients. Haematologica 2001;86(4):404-408.

47. Johnston RE, Abdalla SH. Thalidomide in low doses is effective for the treatment of resistant or relapsed multiple myeloma and for plasma cell leukaemia. Leukemia & Lymphoma 2002;43(2):351-354.

48. Juliusson G, Celsing F, Turesson I, et al. Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma [see comment]. British Journal of Haematology Apr 2000;109(1):89-96.

49. Kees M, Dimou G, Sillaber C, et al. Low dose thalidomide in patients with relapsed or refractory multiple myeloma. Leukemia & Lymphoma 2003;44(11):1943-1946.

50. Kroeger N, Shimoni A, Zagrivnaja M, et al. Low dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma. Blood 2004;104(11):Abstract #1646.

51. Kumar S, Gertz MA, Dispenzieri A, et al. Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma. Mayo Clinic Proceedings 2003;78(1):34-39.

52. Neben K, Moehler T, Egerer G, et al. High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. Clinical Cancer Research2001;7(9):2675-2681.

53. Rajkumar SV, Fonseca R, Dispenzieri A, et al. Thalidomide in the treatment of relapsed multiple myeloma. Mayo Clinic Proceedings 2000;75(9):897-901.

54. Richardson P, Schlossman R, Jagannath S, et al. Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity. Mayo Clinic Proceedings 2004;79(7):875-882.

55. Schey SA, Cavenagh J, Johnson R, et al. An UK myeloma forum phase II study of thalidomide; long term follow-up and recommendations for treatment. Leukemia Research 2003;27(10):909-914.

56. Tosi P, Ronconi S, Zamagni E, et al. Salvage therapy with thalidomide in multiple myeloma patients relapsing after autologous peripheral blood stem cell transplantation. Haematologica 2001;86(4):409-413.

57. Tosi P, Zamagni E, Cellini C, et al. Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma. Haematologica 2002;87(4):408-414.

58. Waage A, Gimsing P, Juliusson G, et al. Early response predicts thalidomide efficiency in patients with advanced multiple myeloma. British Journal of Haematology 2004;125(2):149-155.

59. Yakoub-Agha I, Moreau P, Leyvraz S, et al. Thalidomide in patients with advanced multiple myeloma. Hematology Journal 2000;1(3):186-189.

60. Yakoub-Agha I, Attal M, Dumontet C, et al. Thalidomide in patients with advanced multiple myeloma: a study of 83 patients―report of the Intergroupe Francophone du Myelome (IFM). Hematology Journal 2002;3(4):185-192.

61. Rajkumar SV, Blood E, Vesole DH, et al. Thalidomide plus dexamethasone versus dexamethasone alone in newly diagnosed multiple myeloma (E1A00): Results of a phase III trial coordinated by the Eastern Cooperative Oncology Group. Blood 2004;104(11):Abstract #205.

62. Rajkumar SV, Blood E, Vesole DH,á, et al. A randomised phase III trial of thalidomide plus dexamethasone versus dexamethasone in newly diagnosed multiple myeloma (E1A00): A trial coordinated by the Eastern Cooperative Oncology Group. Journal of Clinical Oncology 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2004;22(14S):Abstract #6508.

63. Ludwig H, Drach J, Tóthová E, et al. Thalidomide-Dexamethason versus Melphalan-Prednisolone as first line treatment in elderly patients with multiple myeloma: an interim analysis. 2005 ASCO Annual Meeting:Abstract #6537.

64. Alexanian R, Weber D, Anagnostopoulos A, et al. Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma [Review]. Seminars in Hematology 2003;40(4 Suppl 4):3-7.

65. Rajkumar SV, Hayman S, Gertz MA, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. Journal of Clinical Oncology 2002;20(21):4319-4323.

66. Rajkumar SV, Dingli D, Nowakowski G, et al. Thalidomide and Dexamethasone in newly diagnosed multiple myeloma: long-term results in patients not undergoing upfront autologous stem cell transplantation. 2005 ASCO Annual Meetings:Abstract #6632.

67. Weber D, Rankin K, Gavino M, et al. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. Journal of Clinical Oncology 2003;21(1):16-19.

68. Anagnostopoulos A, Weber D, Rankin K, et al. Thalidomide and dexamethasone for resistant multiple myeloma. British Journal of Haematology Jun 2003;121(5):768-771.

69. Bernardeschi P, Dentico P, Rossi S, et al. Chemoresistant myeloma: phase II clinical study with low-dose thalidomide plus high-dose dexamethasone. Journal of Chemotherapy Nov 2004;16 Suppl 5:90-93.

70. Dimopoulos MA, Zervas K, Kouvatseas G, et al. Thalidomide and dexamethasone combination for refractory multiple myeloma. Annals of Oncology 2001;12(7):991-995.

71. Myers B, Crouch D, Dolan G. Thalidomide treatment in advanced refractory myeloma [see comment]. British Journal of Haematology Dec 2000;111(3):986.

72. Myers B, Grimley C, Dolan G. Thalidomide and low-dose dexamethasone in myeloma treatment [comment]. British Journal of Haematology Jul 2001;114(1):245.

73. Myers B, Dolan G. Analysis of durability of response to thalidomide treatment for relapsed myeloma patients. British Journal of Haematology 2002;118(1):347.

74. Palumbo A, Giaccone L, Bertola A, et al. Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. Haematologica 2001;86(4):399-403.

75. Palumbo A, Bertola A, Falco P, et al. Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma. Hematology Journal 2004;5(4):318-324.

76. Reece DE, Chen C, Trudel S, et al. Thalidomide ± corticosteroids for the treatment of multiple myeloma patients > 70 years of age. Blood 2004;104(11):Abstract #4934.

77. Tosi P, Zamagni E, Cellini C, et al. Thalidomide-induced peripheral neuropathy in newly diagnosed and pre-treated multiple myeloma patients. Blood 2004;104(11):Abstract #4898.

78. Facon T, Mary JY, Hulin C, et al. Randomized clinical trial comparing melphalan-prednisone (MP), MP-thalidomide (MP-THAL) and high-dose therapy using melphalan 100 MG/M2 (MEL100) for newly diagnosed myeloma patients aged 65-75 years. Interim analysis of the IFM 99-06 trial on 350 patients. Blood 2004;104(11):Abstract #206.

79. Palumbo A, Bertola A, Musto P,á, et al. A prospective randomized trial of oral melphalan, prednisone, thalidomide (MPT) vs. oral melphalan, prednisone (MP): an interim analysis. Blood 2004;104(11):Abstract #207.

80. Alexanian R, Wang LM, Weber DM, et al. VTD (Velcade, Thalidomide, Dexamethasone) as primary therapy for newly-diagnosed multiple myeloma. Blood 2004;104(11):Abstract #210.

81. Chanan-Khan AA, Miller KC, McCarthy P,á, et al. VAD-t (Vincristine, Adriamycin, Dexamethasone and Low-Dose Thalidomide) is an effective initial therapy with high response rates for patients with treatment na´ve multiple myeloma (MM). Blood 2004;104(11):Abstract #3463.

82. Dimopoulos MA, Repoussis P, Terpos E, et al. Primary treatment with pulsed melphalan, dexamethasone, thalidomide (MDT) for symptomatic patients with multiple myeloma >75 years of age. Blood 2004;104(11):Abstract #1482.

83. Hassoun H, Reich L, Klimek VM, et al. Doxorubicin and dexamethasone followed by thalidomide and dexamethasone (AD-TD) as initial therapy for symptomatic patients with multiple myeloma. Blood 2004;104(11):Abstract #2409.

84. Klueppelberg U, Smith E, Chen L, et al. First-line treatment of multiple myeloma with a combination of thalidomide, dexamethasone, and zoledronate (TDZ) in an inner-city population with high hiv prevalence. Blood 2004;104(11):Abstract #4932.

85. Klueppelberg U, Chen L, Aloba CM, et al. First-line, long-term treatment of multiple myeloma with thalidomide, dexamethasone, and zoledronate in combination (TDZ). Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition);22(14S):Abstract #6702.

86. Klueppelberg U, Shapira I, Chen L, et al. Long-term treatment of newly-diagnosed multiple myeloma with low-dose thalidomide, dexamethasone and zoledronate (TDZ). 2005 ASCO Annual Meeting:Abstract #6697.

87. Schutt P, Ebeling P, Buttkereit U, et al. Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma. European Journal of Haematology Jan 2005;74(1):40-46.

88. Zervas K, Dimopoulos MA, Hatzicharissi E, et al. Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study. Annals of Oncology 2004;15(1):134-138 %O (139) English.

89. Badros AZ, Goloubeva O, Ratterree B, et al. Phase II trial of oblimersen sodium (G3139), dexamethasone (Dex) and thalidomide (Thal) in relapsed multiple myeloma patients (Pts). Blood 2004;104(11):Abstract #2400.

90. Bibas M, Andriani A, Viva F, et al. Intermittent low doses of thalidomide in the maintenance treatment of multiple myeloma. Blood 2004;104(11):Abstract #4927.

91. Chanan-Khan AA, Miller KC, McCarthy P, et al. A phase II study of velcade (V), doxil (D) in combination with low-dose thalidomide (T) as salvage therapy for patients (pts) with relapsed (rel) or refractory (ref) multiple myeloma (MM) and Waldenstorm Macroglobulinemia (WM): encouraging preliminary results. Blood 2004;104(11):Abstract #2421.

92. Biagi JJ, Mileshkin L, Grigg AP, et al. Efficacy of thalidomide therapy for extramedullary relapse of myeloma following allogeneic transplantation. Bone Marrow Transplantation 2001;28(12):1145-1150.

93. Ciepluch H, Baran W, Hellmann A. Combination of pamidronate and thalidomide in the therapy of treatment-resistant multiple myeloma. Medical Science Monitor 2002;8(4):P131-136.

94. Dimopoulos MA, Hamilos G, Zomas A, et al. Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma. Hematology Journal 2004;5(2):112-117.

95. Garcia-Sanz R, Gonzalez-Porras JR, Hernandez JM, et al. The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma. Leukemia 2004;18(4):856-863.

96. Hollmig K, Stover J, Talamo G, et al. Bortezomib (Velcade™) + Adriamycin™ + Thalidomide + Dexamethasone (VATD) as an effective regimen in patients with refractory or relapsed multiple myeloma (MM). Blood 2004;104(11):Abstract #2399.

97. Kasper B, Moehler T, Neben K, et al. Combination therapy of Thalidomide and Peginterferon in patients with progressive multiple myeloma. Annals of Oncology Jan 2004;15(1):176-177.

98. Kropff MH, Lang N, Bisping G, et al. Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma. British Journal of Haematology 2003;122(4):607-616.

99. Mileshkin L, Biagi JJ, Mitchell P, et al. Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age. Blood 2003;102(1):69-77.

100. Mileshkin LR, Roberts A, Ganju V, et al. Quality of life (QOL) assessment in patients with relapsed/refractory multiple myeloma (MM) treated with thalidomide (T) plus celecoxib (Cxb). 2005 ASCO Annual Meeting:Abstract #8233.

101. Offidani M, Corvatta L, Marconi M, et al. Common and rare side-effects of low-dose thalidomide in multiple myeloma: focus on the dose-minimizing peripheral neuropathy. European Journal of Haematology 2004;72(6):403-409.

102. Offidani M, Corvatta L, Marconi M, et al. Thalidomide plus oral melphalan compared with thalidomide alone for advanced multiple myeloma. Hematology Journal 2004;5(4):312-317.

103. Suvannasankha A, Fausel C, Juliar BE, et al. Final report of a phase II study of oral cyclophosphamide, thalidomide, and prednisone (CTP) for patients with relapsed or refractory multiple myeloma: a Hoosier Oncology Group Trial: HEM01-21. 2005 ASCO Annual Meeting:Abstract #6591.

104. Teoh G, Hwang W, Koh LP, et al. Low dose dexamethasone and thalidomide with higher frequency zoledronic acid (dtZ) for multiple myeloma. Blood 2004;104(1):Abstract #4915.

105. Williams CD, Byrne JL, Sidra G, et al. Combination chemotherapy with cyclophosphamide, thalidomide and dexamethasone achieves a high response rate in patients with newly diagnosed, VAD-refractory and relapsed myeloma. Blood 2004;104(11):Abstract #1499.

106. Williams CC, Haura EB, Antonia SJ, et al. Phase II trial of docetaxel and gefitinib as first-line therapy for elderly patients with advanced nonsmall ell lung cancer (ANSCLC). Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition);22(14S (July 15 Supplement)):7342.

107. Zangari M, Barlogie B, Hollmig K, et al. Marked activity of velcade plus thalidomide (V+T) in advanced and refractory multiple myeloma (MM). Blood 2004;104(11):Abstract #1480.

108. Attal M, Harousseau JL, Leyvraz S, et al. Maintenance treatment with thalidomide after autologous transplantation for myeloma: first analysis of a prospective randomized study of the Intergroupe Francophone du Myelome (IFM 99 02). Blood 2004;104(11):Abstract #535.

109. Barlogie B, Jr., Shaughnessy JD. Early results of total therapy II in multiple myeloma: implications of cytogenetics and FISH. International Journal of Hematology 2002;76(Suppl 1):337-339.

110. Barlogie B, Rasmussen E, Tricot G, et al. Management of patients with multiple myeloma (MM) failing total therapy 2 (TT 2) according to thalidomide (THAL) randomization. Blood 2004;104(11):Abstract #1483.

111. Alexanian R, Weber D, Giralt S, et al. Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy. Annals of Oncology 2002;13(7):1116-1119.

112. Sengar M, Kumar L, Ganessan K, et al. Role of post transplant maintenance therapy in multiple myeloma: results from a developing country. 2005 ASCO Annual Meeting:Abstract #6731.

113. Stewart AK, Chen C, Howson-Jan K, et al. Results of a multi-center randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma following autologous stem cell transplant. Blood 2004;104(11):Abstract #335.

114. Anaissie EJ, Talamo G, Angtuaco E, et al. Avascular necrosis of bone after therapy for multiple myeloma: a study of 561 consecutive patients. Blood 2004;104(11):Abstract#3467.

115. Badros AZ, Siegel E, Bodenner D, et al. Hypothyroidism in patients with multiple myeloma following treatment with thalidomide. American Journal of Medicine 2002;112(5):412-413 %O (439) English.

116. Bowcock SJ, Rassam SM, Ward SM,. Thromboembolism in patients on thalidomide for myeloma. Hematology 2002;7(1):51-53.

117. Fahdi IE, Gaddam V, Saucedo JF, et al. Bradycardia during therapy for multiple myeloma with thalidomide. American Journal of Cardiology 2004;93(8):1052-1055.

118. Hall VC, El-Azhary RA, Bouwhuis S,. Dermatologic side effects of thalidomide in patients with multiple myeloma. Journal of the American Academy of Dermatology 2003;48(4):548-552.

119. Singh V, Klinge A, Luminari S, et al. Understanding thalidomide-associated deep vein thrombosis/pulmonary emboli (DVT/PE): comparison of quality and information included in adverse event reports from clinical trials, clinical practice, STEPS, and the medical literature. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition);22(14S):Abstract #3142.

120. Spencer A, Roberts A, Neeman T, et al. Renal safety evaluation of zoledronic acid and thalidomide when used as post-stem cell transplant maintenance therapy in multiple myeloma. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition);22(14S):Abstract #6655.

121. Tosi P, Zamagni E, Cellini C, et al. Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma. European Journal of Haematology Mar 2005;74(3):212-216.

122. Zangari M, Anaissie E, Barlogie B, et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 2001;98(5):1614-1615.

123. Zangari M, Saghafifar F, Anaissie E, et al. Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. Blood Coagulation & Fibrinolysis 2002;13(3):187-192.

124. Zangari M, Siegel E, Barlogie B, et al. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood 2002;100(4):1168-1171.

125. Zangari M, Barlogie B, Lee CK, et al. Protective effect of VELCADE® on thalidomide-associated deep vein thrombosis (DVT). Blood 2004;104(11):Abstract #4914.

126. Zangari M, Barlogie B, Anaissie E, et al. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. British Journal of Haematology Sep 2004;126(5):715-721.

127. Mileshkin L, Prince HM, Seymour JF, et al. Serum MUC-1 as a marker of disease status in multiple myeloma patients receiving thalidomide. British Journal of Haematology 2003;123(4):747-748.

128. Dmoszynska A, Bojarska-Junak A, Domanski D, et al. Production of proangiogenic cytokines during thalidomide treatment of multiple myeloma. Leukemia & Lymphoma 2002;43(2):401-406.

129. Neben K, Moehler T, Kraemer A, et al. Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion. British Journal of Haematology 2001;115(3):605-608.

130. Thompson MA, Witzig TE, Kumar S, et al. Plasma levels of tumour necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myeloma. British Journal of Haematology 2003;123(2):305-308.

131. Neben K, Mytilineos J, Moehler TM, et al. Polymorphisms of the tumor necrosis factor-alpha gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma. Blood 2002;100(6):2263-2265.

132. Jaksic WJ, Trudel S, Chang H, et al. t(4;14) Positive multiple myeloma is chemosensitive to dexamethasone and/or thalidomide but not alkylating agents: rapid relapse and not primary drug resistance explains poor outcomes. Blood 2004;104(11):Abstract #2417.

133. Shaughnessy J, Jr., Tian E, Sawyer J, et al. Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II. British Journal of Haematology 2003;120(1):44-52.

134. Neben K, Moehler T, Benner A, et al. Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma. Clinical Cancer Research2002;8(11):3377-3382.

135. Tosi P, Zamagni E, Cellini C, et al. Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure. European Journal of Haematology 2004;73(2):98-103.

136. Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma [see comment][erratum appears in N Engl J Med 2004 Jun17;350(25):2628]. New England Journal of Medicine Dec 25 2003;349(26):2495-2502.

137. Harousseau JL. Management of multiple myeloma [Review]. Reviews in Clinical & Experimental Hematology 2002;6(3):253-275.

138. Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000;96(9):2000.

139. Cavo M, Zamagni, E.Tosi P, et al. Superiority of first-line thalidomide-dexamethasone over vincristine-doxorubicin-dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Blood 2004;104(11):Abstract#1489.

140. Cavo M, Zamagni E, Tosi P, et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 2006;106(1):35-39.

141. Richardson P, Anderson K. Immunomodulatory analogs of thalidomide: an emerging new therapy in myeloma. Journal of Clinical Oncology 2004;22(16):3212-3214.

Return to Contents
Proceed to Included Articles

The information on this page is archived and provided for reference purposes only.

 

AHRQ Advancing Excellence in Health Care